Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib ('Iressa', ZD1839)

Cancer Science
Akira HirataMayumi Ono

Abstract

The development of gefitinib ('Iressa', ZD1839) by targeting the EGFR tyrosine kinase is a recent therapeutic highlight. We have reported that gefitinib is antiangiogenic in vitro, as well as in vivo. In this study, we asked if the anti-angiogenic action of gefitinib is due to a direct effect on activation of vascular endothelial cells by EGF. EGF, as well as VEGF, caused pronounced angiogenesis in an avascular area of the mouse cornea, and i.p. administration of gefitinib almost completely blocked the response to EGF, but not to VEGF. Immunohistochemical analysis demonstrated phosphorylation of EGFR by EGF in the neovasculature, and gefitinib markedly reduced this effect. Gefitinib also inhibited downstream activation of ERK 1/2 via EGFR in cultured microvascular endothelial (HMVE) cells. These findings suggest that the anti-angiogenic effect of gefitinib in the vascular endothelial cells of neo-vasculature is partly attributable to direct inhibition of EGFR activation, and that endothelial cells in malignant tumors play a critical role in the cancer therapeutic efficacy of gefitinib.

References

Feb 1, 1976·Journal of the National Cancer Institute·M A Gimbrone, P M Gullino
Apr 20, 1990·Cell·A Ullrich, J Schlessinger
May 1, 1996·Journal of Neuropathology and Experimental Neurology·T BöhlingM Haltia
Jun 10, 1997·Proceedings of the National Academy of Sciences of the United States of America·P RockwellC A Stein
Sep 23, 1998·Molecular Medicine Today·M WidschwendterM G Mörtl
Aug 24, 1999·Pharmacology & Therapeutics·J R Woodburn
Dec 29, 2000·Drugs·J Baselga, S D Averbuch
Apr 20, 2001·Experimental Eye Research·Y NakamuraS Kinoshita
Jun 28, 2001·Oncogene·J Mendelsohn, J Baselga
Aug 17, 2001·Internal Medicine·M KuwanoM Ono
Oct 24, 2001·Current Opinion in Oncology·C L Arteaga, D H Johnson
Dec 12, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Hoe Suk KimGou Young Koh
May 22, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Shintaro NakaoMayumi Ono

❮ Previous
Next ❯

Citations

Aug 24, 2010·Journal of Neuro-oncology·Gregory J ChenDavid Zagzag
Nov 3, 2005·Nature Clinical Practice. Oncology·Carolyn I Sartor
May 25, 2006·Current Opinion in Oncology·Alexandre BozecGerard Milano
Mar 19, 2013·The Journal of Biological Chemistry·Matthew S WaitkusPaul E DiCorleto
Mar 11, 2005·Expert Opinion on Therapeutic Targets·Kosuke ShimizuNaoto Oku
Mar 22, 2007·Expert Opinion on Therapeutic Targets·Eunok Im, Andrius Kazlauskas
May 22, 2010·The American Journal of Pathology·Hiroaki ShimoyamadaHitoshi Kitamura
Sep 27, 2007·Journal of Cellular Physiology·Antonella De LucaNicola Normanno
Mar 25, 2006·International Journal of Cancer. Journal International Du Cancer·Niels ReinmuthMichael Thomas
Oct 12, 2013·Anti-cancer Drugs·Margherita Ratti, Gianluca Tomasello
Oct 3, 2013·Asian Pacific Journal of Cancer Prevention : APJCP·De-Jie ZhengJun-Dong Gu
Oct 1, 2005·Journal of Neuro-oncology·Mark W Kieran
Oct 13, 2006·Journal of Neuro-oncology·Robert M BeatyGregory J Riggins
Mar 7, 2020·Nature Communications·Amber N StratmanBrant M Weinstein
Apr 14, 2005·Molecular Cancer Therapeutics·Seungwon KimJeffrey N Myers
Dec 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mayumi Ono, Michihiko Kuwano
Dec 24, 2005·Molecular Cancer Therapeutics·Alexandre BozecGerard Milano
Apr 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Urszula DoughertyMarc Bissonnette
Jun 17, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patrizia SiniJeanette Wood
Apr 4, 2021·Cancers·Beate HeissigKoichi Hattori
Mar 19, 2014·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Zhaofei LiuFan Wang
Mar 20, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Haitao HuQin Jiang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.